Correspondence to "Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy1"
- PMID: 38226721
- DOI: 10.1111/all.16020
Correspondence to "Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy1"
Comment in
-
Response to Correspondence to "Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy".Allergy. 2024 Jun;79(6):1637-1638. doi: 10.1111/all.16104. Epub 2024 Mar 25. Allergy. 2024. PMID: 38525846 No abstract available.
Comment on
-
Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy.Allergy. 2023 Oct;78(10):2756-2766. doi: 10.1111/all.15788. Epub 2023 Jun 27. Allergy. 2023. PMID: 37366581 Clinical Trial.
References
REFERENCES
-
- de Kam PJ, Zielen S, Bernstein JA, et al. Short‐course subcutaneous treatment with PQ grass strongly improves symptom and medication scores in grass allergy. Allergy Oct. 2023;78(10):2756‐2766. doi:10.1111/all.15788
-
- Durham SR, Shamji MH. Allergen immunotherapy: past, present and future. Nat Rev Immunol. 2023;23(5):317‐328. doi:10.1038/s41577-022-00786-1
-
- Hesse L, Oude Elberink JNG, van Oosterhout AJM, Nawijn MC. Allergen immunotherapy for allergic airway diseases: use lessons from the past to design a brighter future. Pharmacol Ther. 2022;237:108115. doi:10.1016/j.pharmthera.2022.108115
-
- Jutel M, Agache I, Bonini S, et al. International consensus on allergen immunotherapy II: mechanisms, standardization, and pharmacoeconomics. J Allergy Clin Immunol. 2016;137(2):358‐368. doi:10.1016/j.jaci.2015.12.1300
-
- Golebski K, Layhadi JA, Sahiner U, et al. Induction of IL‐10‐producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response. Immunity. 2021;54(2):291‐307.e7. doi:10.1016/j.immuni.2020.12.013
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical